Cytokine release syndrome (CRS) and neurological events (NEs) were not associated with long-term detriment in overall health-related quality of life (HR-QOL)in patients with relapsed or refractory large B-cell non-Hodgkin lymphoma who responded to treatment with the CAR T-cell therapy lisocabtagene maraleucel (liso-cel) in the open-label Phase 1 TRANSCEND trial. The findings were presented at the 2022 ASCO Quality Care Symposium in Boston in October.
Patients who responded to liso-cel were stratified into 3 groups: those who experienced both CRS and NEs, those who experienced CRS or NEs but not both, and those who experienced neither adverse effect. HR-QOL was evaluated with the European Organisation for Research and Treatment of Cancer core quality of life questionnaire (QLQ-C30) and the EuroQol–5 Dimension 5-level instrument.
Among patients who developed CRS, NEs, or both, QLQ-C30 functional and fatigue scores reached their lowest point about 1 month after liso-cel infusion, followed by a return to baseline status by about 2 months post infusion. By contrast, patients who developed no CRS or NEs saw no initial decrease in HR-QOL scores and showed a trend toward improvement over time.
The findings “indicate a need for discussion with patients before treatment and early symptom monitoring and management of CRS or NEs,” reported first author Donald Patrick, PhD, of the University of Washington and co-authors.
- Patrick D, McManus S, Podger L, et al. Impact of acute toxicities associated with chimeric antigen receptor (CAR) T-cell therapy on health-related quality of life (HRQOL) in relapsed or refractory (R/R) large B-cell lymphoma (LBCL)